Massive Bio, Inc., a leader in precision medicine and artificial intelligence (AI)-enabled, business-patient-centric clinical trial matching, announced its newly developed “Hub” aimed to build strategic partnerships with some of the most prominent Just-in-Time (JIT) vendors and provider clinical research teams, looking to facilitate the largest JIT oncology clinical trial network in the world. Massive Bio joins forces with select vendors to accelerate oncology enrollment solutions and optimize workflow efficiencies for global biopharmaceutical sponsors.
TrialSite News interviewed Massive Bio’s founder early in 2019. We found that they are implementing a disruptive model in the pursuit of bringing world-class clinical research to patients, and, conversely, patients to clinical research.
Their proprietary Synergy AI is even the subject of a published in Clinicaltrials.gov. In the study, they include an international registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool powered by a virtual tumor boards (VTB) program, and its clinical impact on patients with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact and potential outcomes of the intervention.
Follow the source below to read the entire press release.